Posts for ARROWHEAD PHARMACEUTICALS, INC. ($ARWR)

Explore Arrowhead Pharmaceuticals' Q4 2024 report highlighting a $173.1M net loss, $578.3M in securities, and strategic partnerships worth up to $14.1B. Investment recommendation: Hold.

Discover Arrowhead Pharmaceuticals, Inc.'s latest 8-K filing on February 10, 2025, detailing critical updates for investors and stakeholders. Ticker: ARWR, NASDAQ.

Discover the latest insights from Arrowhead Pharmaceuticals' 8-K filing, detailing crucial events and updates for investors on December 11, 2024.